Navigation Links
Clinical and Histopathological Results Using Pollogen's TriPollar(TM) Radio Frequency Technology Published in the June Issue of the Journal of Cosmetic and Laser Therapy

TEL AVIV, Israel, June 17 /PRNewswire/ -- A recent clinical study using Pollogen's regen(TM) device- the latest aesthetic solution powered by 3rd generation TriPollar(TM) technology, confirms the safety and efficacy of TriPollar(TM) technology in reducing fat and collagen remodeling. The peer reviewed paper entitled "Clinical and histopathological results following TriPollar(TM) radiofrequency skin treatments", authored by Dr. Haim Kaplan and Dr. Andrea Gat, has been published in the June issue of the Journal of Cosmetic and Laser Therapy (Volume 11, Issue 2 June 2009 , pages 78 - 84). The abstract is available online at: an&hash=843258562

(Due to the length of this URL, it may be necessary to copy and paste this hyperlink into your Internet browser's URL address field. Remove the space if one exists.)

The study provides further evidence that TriPollar(TM) technology is a safe and effective non-invasive solution for skin tightening and body reshaping.

The study involved twelve patients who underwent an average of seven weekly treatment sessions on different body areas including the face, neck, arms, hands and abdomen. One patient consented to a series of TriPollar(TM) treatments prior to her scheduled abdominoplasty and a controlled histological analysis was performed on skin samples taken during the surgery. The histopathological examination revealed marked differences between the treated and non- treated abdominal skin areas. An increase of 49% in dermal thickness due to neo collagen regeneration, focal thickening and remodeling of collagen fibers and focal shrinkage of fat cells were measured following the TriPollar(TM) treatments.

Patient satisfaction was also measured and the study confirmed clear satisfaction with achieved clinical results.

Dr. Kaplan stated: "The regen TriPollar device is an RF system that can safely and effectively be used for body contouring, particularly on the abdomen, thighs and arms, as well as for the treatment of cellulite, skin laxity and facial wrinkles, given the correct indication. Application of this treatment modality is simple, non-invasive and extremely safe on all skin types. Clinical and histological results have been documented and appear to be maintained for at least several months following a typical treatment course of 8 weekly sessions."

"We are very excited about the latest clinical results that further confirm the marked efficacy of TriPollar(TM) technology in treating a wide variety of aesthetic needs- body contouring, facial rejuvenation and cellulite reduction. The painless, non-invasive solution offers an ideal alternative to surgery-averse patients. Pollogen is dedicated to continuing to develop products that enhance the wellbeing of patients worldwide" commented Dr. Zion Azar Pollogen's Chairman and CEO.

About Pollogen:

Pollogen Ltd. develops, manufactures and markets professional medical aesthetic devices, powered by the TriPollar(TM) 3rd generation Radio Frequency (RF) technology. Invented and perfected by Pollogen, proprietary TriPollar(TM) technology powers a full line of clinically-proven, non-invasive and non-surgical treatment platforms for wrinkles, cellulite, circumference reduction and skin tightening. The flagship aesthetic devices, apollo(TM) and regen(TM) offer customers clinically-proven, safe and effective anti-aging beauty treatments that deliver immediate and long-lasting results. To learn more, please visit the Pollogen website at


    Abigail Marks
    Tel: +972-54-244-5807

SOURCE Pollogen Ltd
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. HEALTHPOINT-Sponsored Venous Leg Ulcer Clinical Trial Enrolls First Subject for Second Phase II Study
2. MacroGenics and Lilly Achieve Targeted Patient Enrollment in PROTEGE, a Global Phase 2/3 Clinical Trial of Teplizumab in Type 1 Diabetes
3. New Legislation Seeks to Boost Participation in Clinical Trials for Rare Diseases
4. When It Comes to Natural Remedies for Hormonal Balance, the Proof Is in the Clinical Research
5. Osteotech Completes Enrollment for DuraTech(TM) BioRegeneration Matrix Clinical Trial
6. Overview of Pixantrone Phase III Clinical Data Presentation at American Society of Clinical Oncology 2009 Annual Meeting Now Available at Clinical Care Options
7. DOR BioPharma Receives EMEA Agreement on the Design of its Confirmatory Phase 3 Clinical Trial of orBec(R) in GI GVHD
8. Meta-Analysis of Clinical Data Showed No Increased Risk of Cardiovascular Events Associated With Exenatide Use: Data Presented at ADA 2009
9. Two New Clinical Studies Show That Limited Exposure to Blood Transfusion Significantly Increases Morbidity and Mortality After Surgery
10. Trius Announces Positive Results From Phase 2 Clinical Trial of Torezolid in Patients With Complicated Skin and Skin Structure Infections
11. Enrollment in Delcaths Pivotal Phase III Metastatic Melanoma Clinical Trial Achieves Seventy-Five Percent Accrual
Post Your Comments:
(Date:12/1/2015)... 1, 2015 Relmada Therapeutics, Inc. (OTCQB: RLMD), a ... pain, announced today that the company will present at the ... 1-3 at the Luxe Sunset Boulevard Hotel in ... of Relmada Therapeutics, will present on Thursday, December 3, at ... . Please register at least 10 minutes prior to ...
(Date:12/1/2015)... DIEGO , Dec. 1, 2015   MabVax ... drug development company, announces it has filed an Investigational ... Drug Administration (FDA) for the Company,s lead fully human ... to FDA acceptance, MabVax plans to initiate the Phase ... --> --> The planned Phase ...
(Date:12/1/2015)... 1, 2015   Craneware, Inc ., the ... today announced the company will showcase a new ... ® solution at the American Society for ... . The new features are focused on simplifying ... and managing enterprise-wide pharmacy charges to ensure compliance ...
Breaking Medicine Technology:
(Date:12/1/2015)... Diego, CA (PRWEB) , ... December 01, 2015 ... ... and scale , Visage Imaging Inc. (“Visage”), a wholly owned subsidiary of Pro ... mobile imaging results enhancements at the Radiological Society of North America (RSNA) 2015 ...
(Date:12/1/2015)... ... December 01, 2015 , ... McLean, VA., ... awarded a fixed price per sprint agile development contract to support the National ... over five years, provides software engineering, infrastructure, as well as operations and sustainment ...
(Date:12/1/2015)... ... December 01, 2015 , ... PYA’s latest white paper, ... addresses a main “pain point” for merging or aligning healthcare provider organizations—when mergers ... is signed. This quick-read guidance suggests that failing to recognize the power ...
(Date:12/1/2015)... (PRWEB) , ... December 01, 2015 , ... With ... footage, and with full control over customization, the possibilities are truly endless, all with ... position randomization, overlay depth position, vertical flip, horizontal flip, depth of field and more, ...
(Date:12/1/2015)... ... December 01, 2015 , ... SonaCare Medical congratulates the University ... Innovation Award on November 18th. This prestigious award recognizes annually organizations that cultivate ... to the medical landscape. , The UCLH team won the award for their ...
Breaking Medicine News(10 mins):